Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according ...

Approximately four in 10 cancer cases worldwide may be preventable, according to a new report.An estimated 7.1 million of the 18.7 million global cancer diagnoses in 2022 — equating to 37.9% — could ...

The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...

Dr. Stacy Lindborg is president and CEO of IMUNON, a clinical-stage company in phase 3 development with a lead DNA-mediated immunotherapy for advanced ovarian cancer. Dr. Lindborg has worked in the ...

Paul Madley, 66, said he doesn't know 'where he would be' without a 'life-saving' cancer treatment, which has now been ...

Natco Pharma receives USFDA approval for Erdafitinib, a generic cancer drug for advanced urothelial carcinoma patients.

As health systems struggle with capacity constraints, workforce shortages and rising patient demand, access has become one of healthcare’s most urgent challenges. At Jefferson Health, leaders ...

The firm is expecting a preliminary data read out from the trial, which is already underway in the US, in the second half of this year.

Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...